Enoblituzumab
Term · Oncology and biomedicine · MLC-T-ONC-013356
An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.
| Identifier | MLC-T-ONC-013356 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | monoclonal antibody MGA271 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013356",
"term": "Enoblituzumab",
"field": "Oncology and biomedicine",
"definition": "An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.",
"synonyms": [
"monoclonal antibody MGA271"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/enoblituzumab/"
}
Record 6,696 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.